Oppenheimer Asset Management Inc. grew its position in shares of Evolent Health Inc (NYSE:EVH) by 9.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 169,973 shares of the technology company’s stock after acquiring an additional 14,366 shares during the period. Oppenheimer Asset Management Inc. owned about 0.21% of Evolent Health worth $2,138,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of EVH. American Century Companies Inc. bought a new position in Evolent Health in the 4th quarter valued at approximately $8,773,000. Vanguard Group Inc lifted its holdings in shares of Evolent Health by 8.3% during the 3rd quarter. Vanguard Group Inc now owns 5,713,530 shares of the technology company’s stock valued at $162,264,000 after buying an additional 439,172 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Evolent Health by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,713,530 shares of the technology company’s stock valued at $162,264,000 after buying an additional 439,172 shares during the period. Standard Life Aberdeen plc lifted its holdings in shares of Evolent Health by 27.3% during the 3rd quarter. Standard Life Aberdeen plc now owns 1,871,543 shares of the technology company’s stock valued at $53,105,000 after buying an additional 401,893 shares during the period. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of Evolent Health by 875.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 424,253 shares of the technology company’s stock valued at $8,464,000 after buying an additional 380,756 shares during the period. Hedge funds and other institutional investors own 99.96% of the company’s stock.
Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Evolent Health from a “buy” rating to a “hold” rating in a report on Friday, May 10th. KeyCorp lowered their price target on Evolent Health from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, March 4th. Finally, ValuEngine cut Evolent Health from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $26.54.
EVH stock traded down $0.04 during trading on Wednesday, reaching $14.50. The company’s stock had a trading volume of 624,000 shares, compared to its average volume of 1,269,439. Evolent Health Inc has a 1 year low of $12.09 and a 1 year high of $29.05. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.96 and a current ratio of 1.96. The firm has a market capitalization of $1.14 billion, a PE ratio of -41.43 and a beta of 1.26.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, May 7th. The technology company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.02. Evolent Health had a negative return on equity of 4.80% and a negative net margin of 12.52%. The business had revenue of $197.80 million during the quarter, compared to analyst estimates of $192.65 million. During the same quarter in the prior year, the business posted $0.02 EPS. Evolent Health’s revenue for the quarter was up 41.6% compared to the same quarter last year. On average, sell-side analysts forecast that Evolent Health Inc will post -0.8 EPS for the current fiscal year.
Evolent Health Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: Do You Need a Fiduciary?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.